Last updated: May 3, 2021
Sponsor: Yonsei University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Circulation Disorders
Stress
Williams Syndrome
Treatment
N/AClinical Study ID
NCT04170751
4-2019-0696
Ages 40-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Adult patients aged 40-80 years who are planning to have thoracoscopic singlelobectomy with unilateral lung ventilation during surgery.
- Patients taking hypertension drug CCB(calcium channel blocker), ARB(angiotensin IIreceptor blocker), ACEi(ACE inhibitor, angiotensin converting enzyme inhibitor) atleast 4 weeks.
- American Society of Anesthesiologists (ASA) classification 2~3
Exclusion
Exclusion Criteria:
- patients with heart failure (NYHA class III~IV)
- patients who are having moderate obstructive lung disease or restrictive lung disease
- Low DLCO (< 75%)
- patients with pulmonary hypertension (mean PAP>25mmHg)
- patients with liver disease (AST level ≥100 IU/mL or ALT ≥ level 50 IU/L) or kidneydisease (Creatine level ≥ 1.5 mg/dL)
- body mass index (BMI) > 30 kg/m2
- patients who cannot read explanation and consent form
- patients who are pregnant
Study Design
Total Participants: 40
Study Start date:
November 18, 2019
Estimated Completion Date:
September 30, 2021
Connect with a study center
Department of Anaesthesiology and Pain Medicine, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine
Seoul, 03722
Korea, Republic ofActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.